Cargando…

Gene expression in active systemic JIA after anti-IL1 and anti-IL6R treatment

Detalles Bibliográficos
Autores principales:	Ogilvie, EM, Samuel, JM, Woo, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334086/ http://dx.doi.org/10.1186/1546-0096-6-S1-P28

Ejemplares similares

Are genetic variants of Caspase-1 and Cryopyrin associated with systemic JIA?
por: Stock, CJ, et al.
Publicado: (2008)

The role of synovial fluid cytokines IL-6, IL-23 and IL-17 in the pathogenesis and persistence of synovial inflammation in JIA patients
por: Tzimouli, V, et al.
Publicado: (2008)

IL-1 receptor antagonist restores IL-18 NK cell axis in systemic JIA
por: Vastert, Sebastiaan J, et al.
Publicado: (2012)

Complicated systemic JIA with macrophage activation syndrome and pulmonary hypertension responsive to a anti IL-1: case report
por: Paim-Marques, Luciana B, et al.
Publicado: (2014)

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008)

Understanding the biology and use of anti-TNF agents in JIA – interim results
por: Lovell, Daniel J, et al.
Publicado: (2012)

Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF
por: Pontikaki, I, et al.
Publicado: (2008)

Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis
por: Baildam, EM, et al.
Publicado: (2008)

Replication of the association of the COG6 gene with juvenile idiopathic arthritis (JIA)
por: Hinks, A, et al.
Publicado: (2011)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy
por: Russo, R, et al.
Publicado: (2011)

Pathogenic roles of IL-6 and IL-6 blocking therapy on rheumatoid arthritis
por: Yoshizaki, K, et al.
Publicado: (2003)

Abatacept for severe anti-TNF-alfa refractory JIA-associated uveitis: one year follow-up
por: Alpigiani, MG, et al.
Publicado: (2011)

A high IL6/IL17 ratio combined with low IL5 expression is correlated with poor survival in squamous cervical cancer
por: Punt, Simone, et al.
Publicado: (2014)

Intratumoral IL-15 potentiates radiation-induced anti-tumor immunity
por: Pilones, Karsten, et al.
Publicado: (2015)

Determing an “autoimmune” phenotype in systemic JIA
por: Fischer, N, et al.
Publicado: (2011)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
por: Kim, Peter S, et al.
Publicado: (2015)

IL-12 primed CD8+ T-cells possess enhanced persistence and anti-tumor efficacy because of greater IL-7 responsiveness
por: Johnson, C Bryce, et al.
Publicado: (2013)

Survey of off-label anti-IL1 treatments in France: preliminary data
por: Rossi-Semerano, L, et al.
Publicado: (2011)

Anti-IL1 therapy in patients with refractory FMF living inGermany
por: Buhl, B, et al.
Publicado: (2015)

Measurement of granulocyte colony-stimulating factor and IL-6, IL-8 and IL-10 as an early predictor for septic patients
por: Razek, A Abdel, et al.
Publicado: (2005)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

The swedish paediatric JIA-registry
por: Magnusson, Bo
Publicado: (2014)

Puberty and disease activity in JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Clinical classification of JIA in Albania
por: Vula, Aurel, et al.
Publicado: (2014)

Impact of a 2-yr anti-TNF treatment on the quality of life in JIA patients: a parent's/patient’s view
por: Diafa, K, et al.
Publicado: (2011)

Electrotransfer of IL-15/IL-15Rα complex for the treatment of established melanoma
por: Shirley, Shawna, et al.
Publicado: (2015)

Recombinant IL1-RA in the early phase of systemic onset JIA: before the onset of arthritis
por: Vastert, SJ, et al.
Publicado: (2011)

Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer
por: Mace, Thomas, et al.
Publicado: (2015)

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

P16-30. Induction of Tim-3 expression by the common gamma-chain cytokines IL-2, IL-7, IL-15 and IL-21
por: Jones, BR, et al.
Publicado: (2009)

Selective costimulation by IL-15R/IL-15, but not IL-2R/IL-2, allows the induction of high numbers of tumor-specific CD8+ T cells by human dendritic cells matured in conditions of acute inflammation
por: Hansen, Morten, et al.
Publicado: (2015)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

Neuroblastoma versus systemic JIA – a diagnostic dilemma
por: Scalzi, Lisabeth, et al.
Publicado: (2012)

Effect of ANA positivity on clinical picture of the JIA: should ANA positive JIA be classified as a different group?
por: Polat, Adem, et al.
Publicado: (2011)

Association between IL2RA and juvenile idiopathic arthritis (JIA) disease severity at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study (CAPS)
por: Hyrich, KL, et al.
Publicado: (2008)

Active immunization (vaccination) against peptides of IL-1β induces self anti-IL-1β antibodies and protects against collagen-induced arthritis
por: Bessis, N, et al.
Publicado: (2005)

KIR-HLA class I combinations in JIA-associated uveitis
por: Parsa, Miriam, et al.
Publicado: (2012)

How does tumour necrosis factor uncouple T-cell receptor-induced IL-2 gene expression in murine T cells?
por: Clark, JM, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_bf79n1r5tsng7t3dkg4fl3j40v